Prostate Cancer最新文献_第9页

A Pilot Study of Laparoscopic Doppler Ultrasound Probe to Map Arterial Vascular Flow within the Neurovascular Bundle during Robot-Assisted Radical Prostatectomy. 腹腔镜多普勒超声探头在机器人辅助根治性前列腺切除术中绘制神经血管束内动脉血流的初步研究。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-06-19 DOI: 10.1155/2013/810715

Ketan K Badani, Edan Y Shapiro, William T Berg, Sarah Kaufman, Ari Bergman, Chris Wambi, Arindam Roychoudhury, Trushar Patel

{"title":"A Pilot Study of Laparoscopic Doppler Ultrasound Probe to Map Arterial Vascular Flow within the Neurovascular Bundle during Robot-Assisted Radical Prostatectomy.","authors":"Ketan K Badani, Edan Y Shapiro, William T Berg, Sarah Kaufman, Ari Bergman, Chris Wambi, Arindam Roychoudhury, Trushar Patel","doi":"10.1155/2013/810715","DOIUrl":"https://doi.org/10.1155/2013/810715","url":null,"abstract":"Purpose. To report on the feasibility of a new Laparoscopic Doppler ultrasound (LDU) technology to aid in identifying and preserving arterial blood flow within the neurovascular bundle (NVB) during robotic prostatectomy (RARP). Materials and Methods. Nine patients with normal preoperative potency and scheduled for a bilateral nerve-sparing procedure were prospectively enrolled. LDU was used to measure arterial flow at 6 anatomic locations alongside the prostate, and signal intensity was evaluated by 4 independent reviewers. Measurements were made before and after NVB dissection. Modifications in nerve-sparing procedure due to LDU use were recorded. Postoperative erectile function was assessed. Fleiss Kappa statistic was used to evaluate inter-rater agreement for each of the 12 measurements. Results. Analysis of Doppler signal intensity showed maintenance of flow in 80% of points assessed, a decrease in 16%, and an increase in 4%. Plane of NVB dissection was altered in 5 patients (56%) on the left and in 4 patients (44%) on the right. There was good inter-rater reliability for the 4 reviewers. Use of the probe did not significantly increase operative time or result in any complications. Seven (78%) patients had recovery of erections at time of the 8-month follow-up visit. Conclusions. LDU is a safe, easy to use, and effective method to identify local vasculature and anatomic landmarks during RARP, and can potentially be used to achieve greater nerve preservation. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"810715"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/810715","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31586414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Androgen receptor-target genes in african american prostate cancer disparities. 非裔美国人前列腺癌差异中的雄激素受体靶基因。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-01-10 DOI: 10.1155/2013/763569

Bi-Dar Wang, Qi Yang, Kristin Ceniccola, Fernando Bianco, Ramez Andrawis, Thomas Jarrett, Harold Frazier, Steven R Patierno, Norman H Lee

{"title":"Androgen receptor-target genes in african american prostate cancer disparities.","authors":"Bi-Dar Wang, Qi Yang, Kristin Ceniccola, Fernando Bianco, Ramez Andrawis, Thomas Jarrett, Harold Frazier, Steven R Patierno, Norman H Lee","doi":"10.1155/2013/763569","DOIUrl":"https://doi.org/10.1155/2013/763569","url":null,"abstract":"The incidence and mortality rates of prostate cancer (PCa) are higher in African American (AA) compared to Caucasian American (CA) men. To elucidate the molecular mechanisms underlying PCa disparities, we employed an integrative approach combining gene expression profiling and pathway and promoter analyses to investigate differential transcriptomes and deregulated signaling pathways in AA versus CA cancers. A comparison of AA and CA PCa specimens identified 1,188 differentially expressed genes. Interestingly, these transcriptional differences were overrepresented in signaling pathways that converged on the androgen receptor (AR), suggesting that the AR may be a unifying oncogenic theme in AA PCa. Gene promoter analysis revealed that 382 out of 1,188 genes contained cis-acting AR-binding sequences. Chromatin immunoprecipitation confirmed STAT1, RHOA, ITGB5, MAPKAPK2, CSNK2A,1 and PIK3CB genes as novel AR targets in PCa disparities. Moreover, functional screens revealed that androgen-stimulated AR binding and upregulation of RHOA, ITGB5, and PIK3CB genes were associated with increased invasive activity of AA PCa cells, as siRNA-mediated knockdown of each gene caused a loss of androgen-stimulated invasion. In summation, our findings demonstrate that transcriptional changes have preferentially occurred in multiple signaling pathways converging (\"transcriptional convergence\") on AR signaling, thereby contributing to AR-target gene activation and PCa aggressiveness in AAs.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"763569"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/763569","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31201096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 48

Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. 剖析前列腺癌发展过程中的主要信号通路。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-04-29 DOI: 10.1155/2013/920612

Henrique B da Silva, Eduardo P Amaral, Eduardo L Nolasco, Nathalia C de Victo, Rodrigo Atique, Carina C Jank, Valesca Anschau, Luiz F Zerbini, Ricardo G Correa

{"title":"Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.","authors":"Henrique B da Silva, Eduardo P Amaral, Eduardo L Nolasco, Nathalia C de Victo, Rodrigo Atique, Carina C Jank, Valesca Anschau, Luiz F Zerbini, Ricardo G Correa","doi":"10.1155/2013/920612","DOIUrl":"https://doi.org/10.1155/2013/920612","url":null,"abstract":"Prostate cancer (PCa) is one of the most common malignancies found in males. The development of PCa involves several mutations in prostate epithelial cells, usually linked to developmental changes, such as enhanced resistance to apoptotic death, constitutive proliferation, and, in some cases, to differentiation into an androgen deprivation-resistant phenotype, leading to the appearance of castration-resistant PCa (CRPCa), which leads to a poor prognosis in patients. In this review, we summarize recent findings concerning the main deregulations into signaling pathways that will lead to the development of PCa and/or CRPCa. Key mutations in some pathway molecules are often linked to a higher prevalence of PCa, by directly affecting the respective cascade and, in some cases, by deregulating a cross-talk node or junction along the pathways. We also discuss the possible environmental and nonenvironmental inducers for these mutations, as well as the potential therapeutic strategies targeting these signaling pathways. A better understanding of how some risk factors induce deregulation of these signaling pathways, as well as how these deregulated pathways affect the development of PCa and CRPCa, will further help in the development of new treatments and prevention strategies for this disease.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"920612"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/920612","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31483822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 54

HMGB1: A Promising Therapeutic Target for Prostate Cancer. HMGB1:前列腺癌的一个有前景的治疗靶点

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-05-12 DOI: 10.1155/2013/157103

Munirathinam Gnanasekar, Ramaswamy Kalyanasundaram, Guoxing Zheng, Aoshuang Chen, Maarten C Bosland, André Kajdacsy-Balla

引用次数: 43

Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers. 半凝集素作为晚期前列腺癌新的预后标志物和潜在的治疗靶点。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-09-24 DOI: 10.1155/2013/519436

Diego J Laderach, Lucas Gentilini, Felipe M Jaworski, Daniel Compagno

引用次数: 17

Emerging molecularly targeted therapies in castration refractory prostate cancer. 去势难治性前列腺癌新出现的分子靶向治疗。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-05-08 DOI: 10.1155/2013/981684

Jesal C Patel, Benjamin L Maughan, Archana M Agarwal, Julia A Batten, Tian Y Zhang, Neeraj Agarwal

{"title":"Emerging molecularly targeted therapies in castration refractory prostate cancer.","authors":"Jesal C Patel, Benjamin L Maughan, Archana M Agarwal, Julia A Batten, Tian Y Zhang, Neeraj Agarwal","doi":"10.1155/2013/981684","DOIUrl":"https://doi.org/10.1155/2013/981684","url":null,"abstract":"Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate cancer. However, despite initial responses, almost all men eventually develop castration refractory metastatic prostate cancer (CRPC) and die of their disease. Over the last decade, it has been recognized that despite the failure of ADT, most prostate cancers maintain some dependence on androgen and/or androgen receptor (AR) signaling for proliferation. Furthermore, androgen independent molecular pathways have been identified as drivers of continued progression of CRPC. Subsequently, drugs have been developed targeting these pathways, many of which have received regulatory approval. Agents such as abiraterone, enzalutamide, orteronel (TAK-700), and ARN-509 target androgen signaling. Sipuleucel-T, ipilimumab, and tasquinimod augment immune-mediated tumor killing. Agents targeting classic tumorogenesis pathways including vascular endothelial growth factor, hepatocyte growth factor, insulin like growth factor-1, tumor suppressor, and those which regulate apoptosis and cell cycles are currently being developed. This paper aims to focus on emerging molecular pathways underlying progression of CRPC, and the drugs targeting these pathways, which have recently been approved or have reached advanced stages of development in either phase II or phase III clinical trials. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"981684"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/981684","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31550019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 25

Advances in Robotic-Assisted Radical Prostatectomy over Time. 机器人辅助根治性前列腺切除术的进步。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-11-12 DOI: 10.1155/2013/902686

Emma F P Jacobs, Ronald Boris, Timothy A Masterson

引用次数: 0

Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. 骨靶向治疗转移性去势抵抗性前列腺癌:不断发展的范式。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-08-28 DOI: 10.1155/2013/210686

Joelle El-Amm, Ashley Freeman, Nihar Patel, Jeanny B Aragon-Ching

{"title":"Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.","authors":"Joelle El-Amm, Ashley Freeman, Nihar Patel, Jeanny B Aragon-Ching","doi":"10.1155/2013/210686","DOIUrl":"https://doi.org/10.1155/2013/210686","url":null,"abstract":"Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone resorption. While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit. Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well. Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"210686"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/210686","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31762529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

Quantifying the ki-67 heterogeneity profile in prostate cancer. 前列腺癌患者ki-67异质性的定量分析。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-10-03 DOI: 10.1155/2013/717080

Shane Mesko, Patrick Kupelian, D Jeffrey Demanes, Jaoti Huang, Pin-Chieh Wang, Mitchell Kamrava

{"title":"Quantifying the ki-67 heterogeneity profile in prostate cancer.","authors":"Shane Mesko, Patrick Kupelian, D Jeffrey Demanes, Jaoti Huang, Pin-Chieh Wang, Mitchell Kamrava","doi":"10.1155/2013/717080","DOIUrl":"https://doi.org/10.1155/2013/717080","url":null,"abstract":"Background: Ki-67 is a robust predictive/prognostic marker in prostate cancer; however, tumor heterogeneity in prostate biopsy samples is not well studied.Methods: Using an MRI/US fusion device, biopsy cores were obtained systematically and by targeting when indicated by MRI. Prostate cores containing cancer from 77 consecutive men were analyzed. The highest Ki-67 was used to determine interprostatic variation. Ki-67 range (highest minus lowest) was used to determine intraprostatic and intralesion variation. Apparent diffusion coefficient (ADC) values were evaluated in relation to Ki-67.Results: Interprostatic Ki-67 mean ± standard deviation (SD) values for NCCN low (L), intermediate (I), and high (H) risk patients were 5.1 ± 3.8%, 7.4 ± 6.8%, and 12.0 ± 12.4% (ANOVA P = 0.013). Intraprostatic mean ± SD Ki-67 ranges in L, I, and H risk patients were 2.6 ± 3.6%, 5.3 ± 6.8%, and 10.9 ± 12.3% (ANOVA P = 0.027). Intralesion mean ± SD Ki-67 ranges in L, I, and H risk patients were 1.1 ± 0.9%, 5.2 ± 7.9%, and 8.1 ± 10.8% (ANOVA P = 0.22). ADC values at Ki-67 > and <7.1% were 860 ± 203 and 1036 ± 217, respectively (P = 0.0029).Conclusions: High risk patients have significantly higher inter- and intraprostatic Ki-67 heterogeneity. This needs to be considered when utilizing Ki-67 clinically.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"717080"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/717080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31857464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. 循环microrna作为前列腺癌的生物标志物:研究进展。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-03-12 DOI: 10.1155/2013/539680

Nikhil Sapre, Luke A Selth

引用次数: 53